Login
Home
Charts
Search
Watchlist
Products

Neogen Chemicals Ltd

NEOGEN·NSE
2,392.10+0.54%Wed, 23 Sept '26

Neogen Chemicals Ltd

NEOGEN
NSE
2,392.10
+0.54%
|Wed, 23 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
7,186Cr
Close
Close Price
2,392.10
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
179.99
PS
Price To Sales
7.76
Revenue
Revenue
926Cr
Rev Gr TTM
Revenue Growth TTM
18.00%
PAT Gr TTM
PAT Growth TTM
5.71%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
162164200180193201203187209220247250
Growth YoY
Revenue Growth YoY%
9.2-11.7-2.19.119.622.51.63.87.99.221.634.0
Expenses
ExpensesCr
136144164149159167166155179188203202
Operating Profit
Operating ProfitCr
262036313535363230324448
OPM
OPM%
16.012.317.917.117.917.217.916.914.414.517.819.3
Other Income
Other IncomeCr
222211-1312214
Interest Expense
Interest ExpenseCr
111110101313131319222121
Depreciation
DepreciationCr
666777767788
PBT
PBTCr
11622161515414561623
Tax
TaxCr
356455142246
PAT
PATCr
8117111110210341117
Growth YoY
PAT Growth YoY%
-19.8-92.818.317.638.4844.3-85.8-10.6-69.3-63.1372.666.8
NPM
NPM%
4.90.68.56.45.75.01.25.51.61.74.66.8
EPS
EPS
3.20.46.44.34.23.80.93.91.31.44.36.3
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
162164200180193201203187209220247250
Growth YoY
Revenue Growth YoY%
9.2-11.7-2.19.119.622.51.63.87.99.221.634.0
Expenses
ExpensesCr
136144164149159167166155179188203202
Operating Profit
Operating ProfitCr
262036313535363230324448
OPM
OPM%
16.012.317.917.117.917.217.916.914.414.517.819.3
Other Income
Other IncomeCr
222211-1312214
Interest Expense
Interest ExpenseCr
111110101313131319222121
Depreciation
DepreciationCr
666777767788
PBT
PBTCr
11622161515414561623
Tax
TaxCr
356455142246
PAT
PATCr
8117111110210341117
Growth YoY
PAT Growth YoY%
-19.8-92.818.317.638.4844.3-85.8-10.6-69.3-63.1372.666.8
NPM
NPM%
4.90.68.56.45.75.01.25.51.61.74.66.8
EPS
EPS
3.20.46.44.34.23.80.93.91.31.44.36.3

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
109121161239306336487686691778862926
Growth
Revenue Growth%
19.011.632.748.328.19.944.840.80.712.610.818.0
Expenses
ExpensesCr
95101132196248272401575581641725772
Operating Profit
Operating ProfitCr
14202943586487112110136137154
OPM
OPM%
13.016.518.018.219.019.117.816.315.917.515.916.6
Other Income
Other IncomeCr
001101158-1069
Interest Expense
Interest ExpenseCr
5810121214192942497583
Depreciation
DepreciationCr
112357121623282830
PBT
PBTCr
81217294144577153504150
Tax
TaxCr
34681213122117151214
PAT
PATCr
5811212931455036352936
Growth
PAT Growth%
1.848.343.090.736.89.342.512.0-28.7-2.3-17.55.7
NPM
NPM%
4.86.36.88.89.49.39.27.35.24.53.33.8
EPS
EPS
5.510.412.313.418.720.014.013.210.913.3
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
109121161239306336487686691778862926
Growth
Revenue Growth%
19.011.632.748.328.19.944.840.80.712.610.818.0
Expenses
ExpensesCr
95101132196248272401575581641725772
Operating Profit
Operating ProfitCr
14202943586487112110136137154
OPM
OPM%
13.016.518.018.219.019.117.816.315.917.515.916.6
Other Income
Other IncomeCr
001101158-1069
Interest Expense
Interest ExpenseCr
5810121214192942497583
Depreciation
DepreciationCr
112357121623282830
PBT
PBTCr
81217294144577153504150
Tax
TaxCr
34681213122117151214
PAT
PATCr
5811212931455036352936
Growth
PAT Growth%
1.848.343.090.736.89.342.512.0-28.7-2.3-17.55.7
NPM
NPM%
4.86.36.88.89.49.39.27.35.24.53.33.8
EPS
EPS
5.510.412.313.418.720.014.013.210.913.3

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
202023232525262626
Reserves
ReservesCr
3050133160414458734763790
Current Liabilities
Current LiabilitiesCr
841171501782184105277331,188
Non Current Liabilities
Non Current LiabilitiesCr
466049131142162174225898
Total Liabilities
Total LiabilitiesCr
1802463554927991,0541,4611,7472,902
Current Assets
Current AssetsCr
1071602312404926567841,0001,393
Non Current Assets
Non Current AssetsCr
74871242523073986787471,509
Total Assets
Total AssetsCr
1802463554927991,0541,4611,7472,902
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
202023232525262626
Reserves
ReservesCr
3050133160414458734763790
Current Liabilities
Current LiabilitiesCr
841171501782184105277331,188
Non Current Liabilities
Non Current LiabilitiesCr
466049131142162174225898
Total Liabilities
Total LiabilitiesCr
1802463554927991,0541,4611,7472,902
Current Assets
Current AssetsCr
1071602312404926567841,0001,393
Non Current Assets
Non Current AssetsCr
74871242523073986787471,509
Total Assets
Total AssetsCr
1802463554927991,0541,4611,7472,902

Cash Flow

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
12-4-35841-30-29196-231
Investing Cash Flow
Investing Cash FlowCr
-13-20-29-135-146-94-216-317-410
Financing Cash Flow
Financing Cash FlowCr
0246351188100237113642
Net Cash Flow
Net Cash FlowCr
-10-1044-25-8-80
Free Cash Flow
Free Cash FlowCr
-2-22-6161-169-133-332-121-647
CFO To PAT
CFO To PAT%
107.9-17.6-120.6266.73.2-60.7-81.8562.7-805.1
CFO To EBITDA
CFO To EBITDA%
40.9-8.5-59.5129.81.6-27.2-26.5143.8-168.6
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
12-4-35841-30-29196-231
Investing Cash Flow
Investing Cash FlowCr
-13-20-29-135-146-94-216-317-410
Financing Cash Flow
Financing Cash FlowCr
0246351188100237113642
Net Cash Flow
Net Cash FlowCr
-10-1044-25-8-80
Free Cash Flow
Free Cash FlowCr
-2-22-6161-169-133-332-121-647
CFO To PAT
CFO To PAT%
107.9-17.6-120.6266.73.2-60.7-81.8562.7-805.1
CFO To EBITDA
CFO To EBITDA%
40.9-8.5-59.5129.81.6-27.2-26.5143.8-168.6

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
8192,0174,3523,2003,1474,0762,9347,186
Price To Earnings
Price To Earnings
28.664.497.564.088.3117.0102.0180.0
Price To Sales
Price To Sales
2.76.08.94.74.65.23.47.8
Price To Book
Price To Book
5.211.09.96.64.15.23.64.6
EV To EBITDA
EV To EBITDA
16.434.552.431.832.234.231.555.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
28.429.129.529.729.630.531.233.333.533.5
OPM
OPM%
13.016.518.018.219.019.117.816.315.917.515.916.6
NPM
NPM%
4.86.36.88.89.49.39.27.35.24.53.33.8
ROCE
ROCE%
21.422.118.414.811.411.78.17.15.35.3
ROE
ROE%
21.829.818.317.110.210.44.74.43.53.5
ROA
ROA%
6.18.58.16.45.64.72.42.01.01.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
8192,0174,3523,2003,1474,0762,9347,186
Price To Earnings
Price To Earnings
28.664.497.564.088.3117.0102.0180.0
Price To Sales
Price To Sales
2.76.08.94.74.65.23.47.8
Price To Book
Price To Book
5.211.09.96.64.15.23.64.6
EV To EBITDA
EV To EBITDA
16.434.552.431.832.234.231.555.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
28.429.129.529.729.630.531.233.333.533.5
OPM
OPM%
13.016.518.018.219.019.117.816.315.917.515.916.6
NPM
NPM%
4.86.36.88.89.49.39.27.35.24.53.33.8
ROCE
ROCE%
21.422.118.414.811.411.78.17.15.35.3
ROE
ROE%
21.829.818.317.110.210.44.74.43.53.5
ROA
ROA%
6.18.58.16.45.64.72.42.01.01.0
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Neogen Chemicals is a specialty manufacturer that has spent over three decades turning two elements - bromine and lithium - into a library of more than 250 chemical building blocks for drugs, crops, electronics and, increasingly, electric vehicle batteries. It began in 1991 with a handful of bromine compounds made in small reactors near Mumbai, survived the destruction of an earlier plant, and transformed itself twice: first by acquiring a larger rival’s bromine operations in 2016, and then by betting on lithium-ion battery materials through a Japanese technology partnership that no other Indian company has secured. The recurring approach is to master a difficult, high-barrier chemistry - bromine first, then lithium - and then stretch it across as many end-uses as possible, so that expertise built for one industry pays for entry into the next. # Business segments Two engines at different stages - a specialty-chemicals core that has been compounding its product range for three decades, and a battery-materials platform built on top of that lithium expertise, now moving from pilot sales to a dedicated greenfield plant. ## 1. Specialty chemicals: the bromine-and-lithium backbone **A portfolio of over 250 bromine- and lithium-based intermediates, sold to more than 30 countries, where the company competes on chemistry depth rather than scale - it makes molecules that others find too complex or too small to bother with.** - **Built on two elements, sold into a dozen industries** - bromine compounds go into drugs, agrochemicals, flame retardants and water treatment; lithium compounds go into cooling systems, construction chemicals and high-temperature greases, so demand never rests on a single sector. - **Custom synthesis locks in customers** - for more than 39 clients, the company develops and manufactures molecules to their exact specifications, often improving the process along the way to cut the customer’s own costs; 23 such products were in the pipeline with a combined revenue potential of roughly Rs. 2,100 crore as of early 2023. - **Raw-material costs are passed through** - lithium prices swing sharply, so the company ties final-product prices to lithium market rates through long-term agreements, insulating its core profitability from input-cost shocks. - **Lithium supply is a three-decade moat** - as India’s largest importer of lithium carbonate and lithium hydroxide for 30 years, with relationships at two of the world’s biggest miners and a China-free supply chain, the company could secure material even during the 2022 crunch, which brought in new customers from the US, Europe and Asia. - **R&D is the factory before the factory** - 123 people including 11 PhDs, or 14% of the workforce, have expanded the product count from 20 in 2001 to 258 today, and the company only makes products where it can bring its own process innovation. ## 2. Battery materials: the lithium-ion electrolyte bet **India’s first non-FEOC-compliant electrolyte manufacturing platform, built on licensed Japanese technology and the company’s own lithium-salts know-how, now shipping to cell makers while a large-scale plant rises at Dahej.** - **Licensed from the leader, not reverse-engineered** - MU Ionic Solutions (a Mitsubishi Chemical-UBE joint venture) granted its first-ever electrolyte manufacturing licence to Neogen, giving it access to technology proven across five plants in Japan, the US, the UK and China. - **Two products, one battery bill of materials** - the business sells both the electrolyte liquid (about 9% of a cell’s cost) and the lithium salts that go inside it (another 10-15% of the electrolyte), so it captures more value per cell than a pure electrolyte blender would. - **Small plant proving, large plant coming** - a 2,000-tonne electrolyte line and a 400-tonne salts line at the existing Dahej SEZ site are already shipping qualification material and generating revenue (Rs. 36 crore in FY26), while a 65-acre greenfield site at Pakhajan will scale that to 30,000 tonnes of electrolyte and 3,000 tonnes of salts. - **Non-FEOC compliance is the entry ticket** - the supply chain is structured to avoid entities from countries of concern, which matters because cell manufacturers selling into the US and European markets need chemistries that qualify for subsidies and trade rules. # Group structure and partners **The battery-materials business sits in a separate subsidiary, while a Japan office and a Hyderabad acquisition extend the company’s reach into organolithium chemistry and strategic partnerships.** - **Neogen Ionics Limited** - a wholly-owned subsidiary formed in March 2023, housing all electrolyte and electrolyte-salt operations, with its own 65-acre land parcel at Pakhajan and a technology licence from MUIS Japan. - **BuLi Chem** - acquired in May 2023 and merged into Neogen in January 2025, this Hyderabad plant brought organolithium capacity (n-Butyl Lithium and related products) that has since been expanded from 120 to 300 tonnes per year through debottlenecking. - **Neogen Chemicals Japan Corporation** - a wholly-owned subsidiary incorporated in July 2024 to deepen ties with Japanese chemical companies and support the battery-materials segment’s partnership network.

Documents — Neogen Chemicals Ltd

  • Q1 FY2027 Earnings Call Transcript (Jun 2026, PDF): https://www.stockscans.in/document/7di3bkl87fnof08y8od6unc1.pdf
  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/nxdxdbryoin5er4rj6ssc4l7.pdf
  • Q3 FY2026 Earnings Call Transcript (Dec 2025, PDF): https://www.stockscans.in/document/auyb0yb0zxrrnv7ez6e68j2w.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/ghbdt98dg5rxnccnocjxshw3.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/39stc91pqzh7pk81ujgdr9c5.pdf
  • Q3 FY2025 Earnings Call Transcript (Dec 2024, PDF): https://www.stockscans.in/document/5f1a8fvre13fthuxwgixnm68.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/2lnhu7bnyu0nptv1etniazcu.pdf
  • Q1 FY2025 Earnings Call Transcript (Jun 2024, PDF): https://www.stockscans.in/document/aso18cm7novzyjjkstuiznaf.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/k463mcbinn9af1t48q78i41d.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/sopac331r12unfkrwps4uu22.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/7qais53gy86s0qemkfegycfu.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/0ldsqazung09em3t3qxr3s82.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/bx65uyacai34n79vtc7ifaxu.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/asmqhcm6sadtc7nl56j0atwh.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/pwupdfm31nsdbvz5ztw6u33u.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/8rd32frwje8te0a83k1ppwmt.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/0pkfz4f2gmnzltogjhmhwrmt.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/zquhkvg7umkf7hpu7xpkbzhs.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/7i08x1cow6j0ox7hetz1o5n6.pdf
  • Q2 FY2026 Investor Presentation (Sep 2025, PDF): https://www.stockscans.in/document/lfig2lcdydd9sxx3l59onfhl.pdf
  • Q1 FY2026 Investor Presentation (Jun 2025, PDF): https://www.stockscans.in/document/17e34xdj2p00s54vngt2iv14.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/wn22jxhy7fdy4ajt8yys24rf.pdf
  • Q3 FY2025 Investor Presentation (Dec 2024, PDF): https://www.stockscans.in/document/has763zgr2jz26999y8c8htg.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/2skjyw5g306xxqt3vl99b4gq.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/6otwgs5sex06953vzhwqh8rm.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/02cnlnx89xhievliws6g9wr3.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/8yfd21hnsjb60231ixtbyd4e.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/86ugjt173vm1cjozs7qigj0r.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/gu6tbgbua86oyi91zfhfrjq7.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/qjg158tl89ryr6maxpsjttm2.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/r05azqu00f6yq540ulvlykmp.pdf

Concall Transcript Summaries — Neogen Chemicals Ltd

  • Q1 FY2027 Concall Transcript Summary (Jun 2026): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202606/7di3bkl87fnof08y8od6unc1.pdf
  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202603/nxdxdbryoin5er4rj6ssc4l7.pdf
  • Q3 FY2026 Concall Transcript Summary (Dec 2025): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202512/auyb0yb0zxrrnv7ez6e68j2w.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202509/ghbdt98dg5rxnccnocjxshw3.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202503/39stc91pqzh7pk81ujgdr9c5.pdf
  • Q3 FY2025 Concall Transcript Summary (Dec 2024): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202412/5f1a8fvre13fthuxwgixnm68.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202409/2lnhu7bnyu0nptv1etniazcu.pdf
  • Q1 FY2025 Concall Transcript Summary (Jun 2024): https://www.stockscans.in/company/NSE%3ANEOGEN/transcript-notes/202406/aso18cm7novzyjjkstuiznaf.pdf